Visual analog scale |
|
|
|
|
|
|
|
|
|
Pre-treatment |
7.2±1.7 |
7,5 |
3-9 |
|
7.0±1.4 |
7 |
4-9 |
|
0,377 |
Post-treatment |
5.0±1.5 |
5 |
2-7 |
|
3.7±1.5 |
4 |
1-6 |
|
0.002** |
Week 4 (EOT) |
3.3±1.4 |
3 |
1-6 |
|
2.0±1.3 |
2 |
0-5 |
|
0.002** |
§p |
|
0.001** |
|
|
|
0.001** |
|
|
|
Difference |
|
|
|
|
|
|
|
|
|
Pre-/post-treatment |
-2.2±0.6 |
-2 |
|
0.001** |
-3.3±0.9 |
-3 |
|
0.001** |
0.001** |
Pre-treatment/week 4 (EOT) |
-3.9±1.1 |
-4 |
|
0.001** |
-5.0±1.0 |
-5 |
|
0.001** |
0.001** |
Post-treatment/week 4 (EOT) |
-1.7±0.7 |
-2 |
|
0.001** |
-1.6±0.6 |
-2 |
|
0.001** |
0,529 |
Beck Depression Inventory |
|
|
|
|
|
|
|
|
|
Pre-treatment |
12.0±7.4 |
12 |
1-29 |
|
12.0±4.4 |
12 |
2-20 |
|
0,506 |
Post-treatment |
9.4±6.4 |
8 |
0-22 |
|
7.3±3.9 |
7 |
1-16 |
|
0,304 |
Week 4 (EOT) |
6.5±5.0 |
6 |
0-18 |
|
4.6±3.6 |
4 |
0-13 |
|
0,139 |
§p |
|
0.001** |
|
|
|
0.001** |
|
|
|
Difference |
|
|
|
|
|
|
|
|
|
Pre-/post-treatment |
-2.6±2.1 |
-2 |
|
0.001** |
-4.7±2.5 |
-4 |
|
0.001** |
0.001** |
Pre-treatment/week 4 (EOT) |
-5.5±3.1 |
-5 |
|
0.001** |
-7.4±3.1 |
-8 |
|
0.001** |
0.014* |
Post-treatment/week 4 (EOT) |
-2.9±1.8 |
-2,5 |
|
0.001** |
-2.7±2.9 |
-3 |
|
0.001** |
0,612 |
Oswestry Disability Index |
|
|
|
|
|
|
|
|
Pre-treatment |
36.2±18.6 |
33 |
4-72 |
|
35.9±14.3 |
36 |
8-56 |
|
0,950 |
Post-treatment |
27.1±16.1 |
23 |
2-56 |
|
20.7±11. 6 |
16 |
2-44 |
|
0,104 |
Week 4 (EOT) |
17.8±12.4 |
16 |
0-44 |
|
12.2±10.7 |
8 |
0-40 |
|
0.032* |
§p |
|
0.001** |
|
|
|
0.001** |
|
|
|
Difference |
|
|
|
|
|
|
|
|
|
Pre-/post-treatment |
-9.2±4.7 |
-8 |
|
0.001** |
-15.2±6.6 |
-14 |
|
0.001** |
0.001** |
Pre-treatment/week 4 (EOT) |
-18.5±9.1 |
-19 |
|
0.001** |
-23.7±9.7 |
-24 |
|
0.001** |
0.041* |
Post-treatment/week 4 (EOT) |
-9.3±5.5 |
-8 |
|
0.001** |
-8.5±4.5 |
-8 |
|
0.001** |
0,690 |
SD: Standard deviation; EOT: End of treatment; * p<0.05; ** p<0.01; † Wilcoxon signed-rank test; ‡ Mann-Whitney U test; § Friedman test. |